Di Liberto, Maurizio

Publications

Sort by

Co-Author Network

selected publications

PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma. Blood advances. 2023 Academic Article GET IT
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood. 2023 Academic Article GET IT
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 1
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER⁺ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 33
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematology/oncology clinics of North America. 2020 Review GET IT
Times cited: 2
Targeting CDK4/6 in mantle cell lymphoma. Annals of lymphoma. 2020 Academic Article GET IT
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 18
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 50
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 8
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nature communications. 2017 Academic Article GET IT
Times cited: 102
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 191
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 55
CCMCL1: a new model of aggressive mantle cell lymphoma. Blood. 2015 Letter GET IT
Times cited: 5
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer research. 2015 Academic Article GET IT
Times cited: 39
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 212
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell cycle (Georgetown, Tex.). 2013 Academic Article GET IT
Times cited: 2040
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Academic Article GET IT
Times cited: 68
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 81
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 35
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer research. 2008 Academic Article GET IT
Times cited: 95
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer research. 2006 Academic Article GET IT
Times cited: 194
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer research. 2005 Academic Article GET IT
Times cited: 93
Dynamic transport of SNARE proteins in the Golgi apparatus. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 27
Concerted auto-regulation in yeast endosomal t-SNAREs. The Journal of biological chemistry. 2005 Academic Article GET IT
Times cited: 12
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005 Academic Article GET IT
Times cited: 168
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proceedings of the National Academy of Sciences of the United States of America. 2004 Academic Article GET IT
Times cited: 50
Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis. European journal of nuclear medicine and molecular imaging. 2004 Academic Article GET IT
Times cited: 46
Countercurrent distribution of two distinct SNARE complexes mediating transport within the Golgi stack. Molecular biology of the cell. 2004 Academic Article GET IT
Times cited: 75
Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Molecular and cellular biology. 2000 Academic Article GET IT
Times cited: 145
A transcription activator with restricted tissue distribution regulates cell-specific expression of alpha1(XI) collagen. The Journal of biological chemistry. 1997 Academic Article GET IT
Times cited: 12
Comparative analysis of fibrillar and basement membrane collagen expression in embryos of the sea urchin, Strongylocentrotus purpuratus. Zoological science. 1997 Academic Article GET IT
Times cited: 13
Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK. Science (New York, N.Y.). 1997 Academic Article GET IT
Times cited: 414
Overlapping pathways mediate the opposing actions of tumor necrosis factor-alpha and transforming growth factor-beta on alpha 2(I) collagen gene transcription. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 105
Complete primary structure of a sea urchin type IV collagen alpha chain and analysis of the 5' end of its gene. The Journal of biological chemistry. 1993 Academic Article GET IT
Times cited: 36
Pro-alpha 2(V) collagen gene; pairwise analysis of the amino-propeptide coding domain, and cross-species comparison of the promoter sequence. Connective tissue research. 1993 Academic Article GET IT
Times cited: 6
Identification of an upstream regulatory region essential for cell type-specific transcription of the pro-alpha 2(V) collagen gene (COL5A2). The Journal of biological chemistry. 1992 Academic Article GET IT
Times cited: 25
Complex and diversified regulatory programs control the expression of vertebrate collagen genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1990 Review GET IT
Times cited: 88
Analysis of the promoter region and the N-propeptide domain of the human pro alpha 2(I) collagen gene. Nucleic acids research. 1985 Academic Article GET IT
Times cited: 27
Releasing effect of thymidine on G1 phase arrest of erythroleukemia cells caused by FUDR and HMBA. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1984 Academic Article GET IT
Analysis of the 3' end of the human pro-alpha 2(I) collagen gene. Utilization of multiple polyadenylation sites in cultured fibroblasts. The Journal of biological chemistry. 1983 Academic Article GET IT
Times cited: 93
Studies on the structure and possible function of the RNA "cap" in developing sea urchins. Cell differentiation. 1977 Academic Article GET IT
Times cited: 3

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance awarded by Leukemia & Lymphoma Society, Inc. Co-Investigator 2018 - 2023

Mechanism-Based Targeting of Mantle Cell Lymphoma awarded by National Cancer Institute Key Personnel 2018 - 2024

more ...

less ...

Background

education and training

Ph.D., University of Palermo, Faculty of Medicine (Italy) 1976

Contact

full name

Maurizio Di Liberto

primary email

mad2008@med.cornell.edu

VIVO Weill Cornell Medical College

Maurizio Di Liberto Assistant Professor of Research in Pathology and Laboratory Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email